{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:31:57Z","timestamp":1792081917442,"version":"4.4.0"},"reference-count":26,"publisher":"Royal College of Psychiatrists","issue":"5","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":7916,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1996,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We investigated whether antagonism of \u03b1<jats:sub>2<\/jats:sub>adrenergic receptors would augment treatment response in schizophrenia, by administering idazoxan, an \u03b1<jats:sub>2<\/jats:sub>antagonist drug, to treatment-resistant patients on typical neuroleptics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Seventeen hospitalised treatment-resistant patients with DSM\u2013III\u2013R schizophrenia or schizoaffective disorder were studied on typical neuroleptic treatment, on treatment with idazoxan plus typical neuroleptic, and after discontinuation of idazoxan, in fixed, non-random order, and under double-blind, placebo-controlled conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The addition of idazoxan to fluphenazine treatment resulted in significant reductions of global psychosis and total, positive and negative symptoms on the Brief Psychiatric Rating Scale, compared to neuroleptic treatment alone. Symptom improvement significantly correlated with idazoxan-induced changes in indices of noradrenergic function. In a subgroup of patients, idazoxan plus typical neuroleptic treatment compared favourably with clozapine treatment, when both were compared to typical neuroleptic treatment alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The antagonism of \u03b1<jats:sub>2<\/jats:sub>receptors augmented therapeutic response to typical neuroleptic treatment in treatment-resistant patients with schizophrenia. This antagonism may contribute to clozapine's superior antipsychotic effects.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.168.5.571","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T05:35:17Z","timestamp":1224048917000},"page":"571-579","source":"Crossref","is-referenced-by-count":104,"title":["Idazoxan and Response to Typical Neuroleptics in Treatment-Resistant Schizophrenia"],"prefix":"10.1192","volume":"168","author":[{"given":"Robert E.","family":"Litman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Ping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Z.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter W.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pickar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000143910_ref9","doi-asserted-by":"publisher","DOI":"10.1007\/BF01244934"},{"key":"S0007125000143910_ref7","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/clinchem\/32.11.2030","article-title":"Simultaneous liquid chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphe-nylalanine in plasma in their responses to inhibition of monoamine oxidase","volume":"32","author":"Eisenhofer","year":"1986","journal-title":"Clinical Chemistry"},{"key":"S0007125000143910_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(93)90016-A"},{"key":"S0007125000143910_ref1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1987"},{"key":"S0007125000143910_ref16","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1176\/ajp.149.6.746","article-title":"G Proteins: implications for psychiatry","volume":"149","author":"Manji","year":"1992","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000143910_ref23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/archpsyc.1992.01820050009001","article-title":"Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine","volume":"49","author":"Overall","year":"1992","journal-title":"Archives of General Psychiatry"},{"key":"S0007125000143910_ref13","first-page":"131","volume-title":"Modern Methods in Pharmacology","author":"Karoum","year":"1982"},{"key":"S0007125000143910_ref15","volume-title":"The New Pharmacotherapy of Schizophrenia","author":"Litman"},{"key":"S0007125000143910_ref21","first-page":"799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1961","journal-title":"Psychological Research"},{"key":"S0007125000143910_ref17","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810300017003"},{"key":"S0007125000143910_ref14","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199308000-00006"},{"key":"S0007125000143910_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90469-7"},{"key":"S0007125000143910_ref3","doi-asserted-by":"publisher","DOI":"10.1038\/npp.1994.1"},{"key":"S0007125000143910_ref10","first-page":"535","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"S0007125000143910_ref12","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"S0007125000143910_ref18","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442554"},{"key":"S0007125000143910_ref6","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.163.4.451"},{"key":"S0007125000143910_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(91)90062-G"},{"key":"S0007125000143910_ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1963.01720150090010"},{"key":"S0007125000143910_ref26","first-page":"9","article-title":"A rating scale for extrapyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"S0007125000143910_ref11","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/19.9.439"},{"key":"S0007125000143910_ref2","volume-title":"The Scale for the Assessment of Negative Symptoms (SANS)","author":"Andreasen","year":"1981"},{"key":"S0007125000143910_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(93)90017-B"},{"key":"S0007125000143910_ref19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0026-895X(25)11119-X","article-title":"[3H]Idazoxan and some other \u03b12-adrenergic drugs also bind with high affinity to a nonadrenergic site","volume":"35","author":"Michel","year":"1989","journal-title":"Molecular Pharmacology"},{"key":"S0007125000143910_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(93)91535-Z"},{"key":"S0007125000143910_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(84)90478-3"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000143910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T19:23:16Z","timestamp":1738437796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000143910\/type\/journal_article"}},"subtitle":["Comparison with the Atypical Neuroleptic, Clozapine"],"short-title":[],"issued":{"date-parts":[[1996,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1996,5]]}},"alternative-id":["S0007125000143910"],"URL":"https:\/\/doi.org\/10.1192\/bjp.168.5.571","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,5]]}}}